Skip to main content
Caplight Logo









vivoVerse

vivoVerse

Private
Austin, TexasHealthcare & Life Scienceshttps://vivoverse.com/

Last Round

Grant

Jul 9, 2024

Total Funding Raised

$4.08M

Company Overview

vivoVerse is a biotechnology company that provides a high-throughput drug screening and toxicology platform using microfluidics, automated imaging, and AI-driven analysis of C. elegans models.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Biotech Equipment, Medical AI

Business Model

B2B

Customer Profile

Hardware Sales, Services & Consulting, Government Contracts

AI Layer

Application

Keywords

drug discoverytoxicology screeninghigh-throughput screeningmicrofluidicsC. elegansphenotypic screeningin vivocontract research organizationCROAI-driven imagingbiotech lab automationalternative testing methodsanimal-free testingNAMsnew approach methodologiesbiotech hardware

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

vivoVerse Comparables

Compare vivoVerse with similar companies based on industry and business-model similarity.

vivoVerse comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
NemaLife
90%
Phylumtech S.A.
83%
Magnitude Biosciences
83%

vivoVerse Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantJul 9, 2024
GrantAug 5, 2023
GrantJul 8, 2020
GrantJul 9, 2019
GrantOct 9, 2018
Accelerator
Feb 21, 2018

Key People

Founding team and executive leadership

Adela Ben-Yakar

Chief Executive Officer and Co-Founder

Founding Team

vivoVerse Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Feb 26, 2025

    Grew 23% QoQ, from 13 to 16 employees.

  • Jul 9, 2024

    Received grant from National Institute of Environmental Health Sciences.

vivoVerse Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

vivoVerse Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about vivoVerse's valuation, stock price, and market status.

Firmographic Details

HeadquartersAustin, Texas
Employee Range12
Year Founded2016
Last FundingJul 9, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?